Literature DB >> 35351278

Neoadjuvant Therapy for Rectal Cancer.

Felipe F Quezada-Diaz1, J Joshua Smith2.   

Abstract

The treatment of locally advanced rectal cancer is challenging and requires a multidisciplinary approach. Neoadjuvant treatment has improved local control by the combination of radiotherapy, surgery, and chemotherapy. However, neoadjuvant treatment has not yet been shown to improve overall survival and is associated with toxicities and late sequelae that impair the quality of life of patients. Currently, different types of neoadjuvant strategies have raised the question about which one is the optimal strategy for rectal cancer treatment. In this article, we explore the different neoadjuvant treatment regimens currently available, their associated benefits and toxicities, and novel approaches in this area.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoradiation; Neoadjuvant therapy; Rectal cancer; Short-course radiotherapy; Total neoadjuvant therapy

Mesh:

Year:  2022        PMID: 35351278      PMCID: PMC9272896          DOI: 10.1016/j.soc.2021.11.008

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   2.402


  57 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.

Authors:  Johan Erlandsson; Torbjörn Holm; David Pettersson; Åke Berglund; Björn Cedermark; Calin Radu; Hemming Johansson; Mikael Machado; Fredrik Hjern; Olof Hallböök; Ingvar Syk; Bengt Glimelius; Anna Martling
Journal:  Lancet Oncol       Date:  2017-02-10       Impact factor: 41.316

3.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; L Wyrwicz; E Tiret; G Brown; C Rödel; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

4.  Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.

Authors:  Andrea Cercek; Campbell S D Roxburgh; Paul Strombom; J Joshua Smith; Larissa K F Temple; Garrett M Nash; Jose G Guillem; Philip B Paty; Rona Yaeger; Zsofia K Stadler; Kenneth Seier; Mithat Gonen; Neil H Segal; Diane L Reidy; Anna Varghese; Jinru Shia; Efsevia Vakiani; Abraham J Wu; Christopher H Crane; Marc J Gollub; Julio Garcia-Aguilar; Leonard B Saltz; Martin R Weiser
Journal:  JAMA Oncol       Date:  2018-06-14       Impact factor: 31.777

5.  Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.

Authors:  In Ja Park; Y Nancy You; Atin Agarwal; John M Skibber; Miguel A Rodriguez-Bigas; Cathy Eng; Barry W Feig; Prajnan Das; Sunil Krishnan; Christopher H Crane; Chung-Yuan Hu; George J Chang
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

6.  Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial.

Authors:  Tina Yen-Ting Chen; Lisette M Wiltink; Remi A Nout; Elma Meershoek-Klein Kranenbarg; Søren Laurberg; Corrie A M Marijnen; Cornelis J H van de Velde
Journal:  Clin Colorectal Cancer       Date:  2014-12-31       Impact factor: 4.481

7.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04.

Authors:  Samuel Y Ngan; Bryan Burmeister; Richard J Fisher; Michael Solomon; David Goldstein; David Joseph; Stephen P Ackland; David Schache; Bev McClure; Sue-Anne McLachlan; Joseph McKendrick; Trevor Leong; Cris Hartopeanu; John Zalcberg; John Mackay
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

Review 8.  Radiation therapy-associated toxicity: Etiology, management, and prevention.

Authors:  Kyle Wang; Joel E Tepper
Journal:  CA Cancer J Clin       Date:  2021-07-13       Impact factor: 508.702

9.  Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Thierry Conroy; Jean-François Bosset; Pierre-Luc Etienne; Emmanuel Rio; Éric François; Nathalie Mesgouez-Nebout; Véronique Vendrely; Xavier Artignan; Olivier Bouché; Dany Gargot; Valérie Boige; Nathalie Bonichon-Lamichhane; Christophe Louvet; Clotilde Morand; Christelle de la Fouchardière; Najib Lamfichekh; Béata Juzyna; Claire Jouffroy-Zeller; Eric Rullier; Frédéric Marchal; Sophie Gourgou; Florence Castan; Christophe Borg
Journal:  Lancet Oncol       Date:  2021-04-13       Impact factor: 41.316

10.  Patient-Reported Bowel Function in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy After Neoadjuvant Therapy: A Case-Control Study.

Authors:  Felipe F Quezada-Diaz; J Joshua Smith; Rosa M Jimenez-Rodriguez; Isaac Wasserman; Emmanouil P Pappou; Sujata Patil; Iris H Wei; Garrett M Nash; Jose G Guillem; Martin R Weiser; Philip B Paty; Julio Garcia-Aguilar
Journal:  Dis Colon Rectum       Date:  2020-07       Impact factor: 4.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.